A Safety Study of NUC-7738 in Patients With Advanced Solid Tumours or Lymphoma
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a two-part, Phase I, dose-escalation study of NUC-7738 administered by intravenous
infusion across two administration schedules.
Part 1 is a dose-escalation study in patients with advanced solid tumours to assess the
safety and tolerability of NUC-7738, in addition to establishing the recommended phase II
dose (RP2D) and dose administration schedule of NUC-7738 for further exploration in Part 2 of
the study.
Part 2 will further evaluate the selected RP2D and designated dosing schedule in an expansion
cohort of approximately 40 additional patients with advanced solid tumours and approximately
12 patients with lymphoma.